Dendritic cell-based cancer vaccination: quo vadis? (Q37259624)

19 August 2017

1 reference

title

Dendritic cell-based cancer vaccination: quo vadis? (English)

1 reference

19 August 2017

1 reference

M Dauer

1

1 reference

19 August 2017

M Schnurr

series ordinal

2

1 reference

19 August 2017

A Eigler

series ordinal

3

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

1041-1053

1 reference

The three Es of cancer immunoediting

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dendritic cells: a journey from laboratory to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Current approaches in dendritic cell generation and future implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Immune monitoring of T-cell responses in cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Peptide and dendritic cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Effect of melanoma on immune function in the regional lymph node basin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Cellular immunity in breast cancer patients completing taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon c

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Ligand recognition by antigen-presenting cell C-type lectin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

The cell biology of cross-presentation and the role of dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Immunostimulatory combinations: designing the next generation of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

Toll-dependent selection of microbial antigens for presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.1041

10.1586/14760584.7.7.1041

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference